BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 35960240)

  • 1. [One-Year Candida Data of the Central Mycology Laboratory: Which Sample, Which Species, How Resistant?].
    Turan D; Aksaray S
    Mikrobiyol Bul; 2022 Jul; 56(3):493-505. PubMed ID: 35960240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Six Antifungal Susceptibilities of 11
    Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
    Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and Antifungal Susceptibility of
    Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.
    Taj-Aldeen SJ; Kolecka A; Boesten R; Alolaqi A; Almaslamani M; Chandra P; Meis JF; Boekhout T
    Infection; 2014 Apr; 42(2):393-404. PubMed ID: 24352810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.
    Diekema DJ; Messer SA; Boyken LB; Hollis RJ; Kroeger J; Tendolkar S; Pfaller MA
    J Clin Microbiol; 2009 Oct; 47(10):3170-7. PubMed ID: 19710283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APX001A
    Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activities of seven antifungal drugs against clinical isolates of Candida parapsilosis complex.
    Khodavaisy S; Badali H; Meis JF; Modiri M; Mahmoudi S; Abtahi H; Salehi M; Dehghan Manshadi SA; Aala F; Agha Kuchak Afshari S; Lotfali E; Ahangarkani F; Rezaie S
    J Mycol Med; 2020 Sep; 30(3):100968. PubMed ID: 32386800
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang W; Zhan M; Wang N; Fan J; Han X; Li C; Liu J; Li J; Hou Y; Wang X; Zhang Z
    J Med Microbiol; 2023 Mar; 72(3):. PubMed ID: 36920840
    [No Abstract]   [Full Text] [Related]  

  • 15. Species distribution and antifungal susceptibility profile of Candida isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran.
    Mirhendi H; Charsizadeh A; Eshaghi H; Nikmanesh B; Arendrup MC
    Med Mycol; 2020 Feb; 58(2):201-206. PubMed ID: 31111910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
    J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
    Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.
    Pfaller MA; Espinel-Ingroff A; Bustamante B; Canton E; Diekema DJ; Fothergill A; Fuller J; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Ostrosky-Zeichner L; Pelaez T; St-Germain G; Turnidge J
    Antimicrob Agents Chemother; 2014; 58(2):916-22. PubMed ID: 24277027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
    J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.